Back to Search Start Over

Troponin is a useful marker in clinical decision making in hospitalized patients with COVID-19 infections.

Authors :
Safarnezhad-Tameshkel, Fahimeh
Motamed, Nima
Karbalaie Niya, Mohammad Hadi
Perumal, Dhayaneethie
Rezaie, Nader
Izadi, Shirin
Ranjbar, Mitra
Yadollahzadeh, Mahdi
Behdad, Behnam
Hemmasi, Gholamreza
Kaveh, Vahid
Anoushirvani, Ali Arash
Malek, Mojtaba
Farahani, Behzad
Eskandari, Ramin
Panahi, Mahshid
Rahimi, Mandana
Emami, Sepideh
Zamani, Farhad
Farrokhpour, Mohsen
Source :
ARYA Atherosclerosis; 2021, Vol. 17 Issue 1, p1-7, 7p
Publication Year :
2021

Abstract

BACKGROUND: COVID-19 was introduced by the World Health Organization (WHO) as a global pandemic. The disease manifestations ranges from a mild common cold to severe disease and death. It has a higher mortality rate in people with a history of comorbidities, including cardiovascular disease (CVD) and can also contribute to cardiac injury. This study was conducted to evaluate the relationship between troponin levels as a cardiac marker and adverse outcomes in this disease. METHODS: The study sample included 438 patients hospitalized with COVID-19; however, the troponin data of 6 patients were not available. The need to be admitted to the intensive care unit (ICU), and death were considered the adverse outcome in patients with COVID-19. Troponin levels were checked in all patients on day 1 and day 3 of hospitalization. Multiple logistic regression analysis was performed to determine whether there was an independent association between the adverse outcomes and troponin enzyme in hospitalized patients with COVID-19. RESULTS: The mean age of patients was 61.29 ± 15.84 years. Among the 432 patients tested on day 1 of hospitalization, 24 patients (5.6%) tested positive (Troponin 1), and among the 303 patients tested on day 3, 13 patients (4.3%) tested positive (Troponin 2). Based on our results, Troponin 1 showed an independent association with both death (3.008 [95%CI = 1.091-8.290]; P = 0.033) and need for ICU admission (8.499 [95%CI = 3.316-21.788]; P < 0.001) in multiple logistic regression analysis. Moreover, the status of Troponin 2 had an independent significant association with both death (4.159 [95%CI = 1.156-14.961]; P = 0.029) and ICU admission (7.796 [95%CI = 1.954-31.097]; P = 0.004). CONCLUSION: Troponin showed a significant association with adverse outcomes in people who were hospitalized with COVID-19. The periodical assessment of this enzyme from the time of hospitalization may improve the clinical decision making of clinicians. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
17353955
Volume :
17
Issue :
1
Database :
Complementary Index
Journal :
ARYA Atherosclerosis
Publication Type :
Academic Journal
Accession number :
158574929
Full Text :
https://doi.org/10.22122/arya.v17i0.2191